Lakefront Biotherapeutics NV LKFT
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -80.99% | -90.39% | 1,203.06% | -11.60% | -11.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -80.99% | -90.39% | 1,203.06% | -11.60% | -11.60% |
| Cost of Revenue | -15.97% | -79.76% | 4.41% | -50.56% | 16.92% |
| Gross Profit | -200.48% | 73.21% | 2,413.04% | 297.31% | -197.53% |
| SG&A Expenses | 63.88% | -9.87% | -11.86% | -55.22% | -2.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 80.91% | 81.75% | -119.77% | -21.27% | -21.27% |
| Total Operating Expenses | 18.71% | -66.61% | -13.78% | -56.37% | 11.13% |
| Operating Income | -358.15% | 55.37% | 1,508.08% | 147.70% | -57.49% |
| Income Before Tax | 101.98% | 109.92% | 4,393.98% | -2,792.15% | -2,792.15% |
| Income Tax Expenses | 175.93% | 104.29% | 882.34% | 104.80% | 104.80% |
| Earnings from Continuing Operations | 101.91% | 109.99% | 4,368.31% | -2,462.93% | -2,462.93% |
| Earnings from Discontinued Operations | 113.03% | -41.41% | -106.06% | -131.65% | -131.65% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.04% | 110.50% | 3,275.15% | -1,341.01% | -1,341.01% |
| EBIT | -358.15% | 55.37% | 1,508.08% | 147.70% | -57.49% |
| EBITDA | -221.11% | 58.95% | 1,749.20% | 228.72% | -40.46% |
| EPS Basic | 102.04% | 110.50% | 3,272.08% | -1,340.35% | -1,340.35% |
| Normalized Basic EPS | -177.70% | 81.49% | -- | 175.81% | -202.03% |
| EPS Diluted | 102.04% | 110.50% | 3,286.69% | -1,340.35% | -1,340.35% |
| Normalized Diluted EPS | -177.51% | 81.49% | -- | 176.15% | -203.35% |
| Average Basic Shares Outstanding | -0.09% | 0.05% | 0.08% | 0.02% | 0.02% |
| Average Diluted Shares Outstanding | 0.12% | 0.05% | -0.17% | -0.43% | -0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |